MARKETS
Markets

Eton Pharmaceuticals Submits FDA Prior Approval Supplement For Its New Formulation Of KHINDIVI Oral Solution

Jul 29, 2026 · 06:54 AM ET· updated 2h ago

New formulation of KHINDIVI (hydrocortisone) oral solution successfully showed bioequivalence to ALKINDI SPRINKLE (hydrocortisone) oral granules, the FDA-approved hydrocortisone granule formulation, and the Company has

Share
Why It Matters

Eton Pharmaceuticals asked the FDA to approve a new liquid version of a medicine that works the same as the granule version already approved. When a company gets approval for a new form of medicine, it shows they're creating products doctors and patients might prefer to use.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.